Russell Investments Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Russell Investments Group’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-206,845	Closed	-$4.17M	–	3159
2021 Q3	$4.17M	Buy	206,845 +28,079	+16%	+$775K	0.01%	1352
2021 Q2	$6.67M	Buy	178,766 +96,476	+117%	+$2.96M	0.01%	1164
2021 Q1	$2.1M	Buy	82,290 +16,698	+25%	+$426K	﹤0.01%	1847
2020 Q4	$1.44M	Sell	65,592 -50,810	-44%	-$1.12M	﹤0.01%	1927
2020 Q3	$2.09M	Buy	116,402 +31,977	+38%	+$662K	﹤0.01%	1656
2020 Q2	$2.14M	Buy	84,425 +80,825	+2,245%	+$1.74M	﹤0.01%	1588
2020 Q1	$66K	Sell	3,600 -25,969	-88%	-$505K	﹤0.01%	2828
2019 Q4	$651K	Buy	+29,569	New	+$595K	﹤0.01%	2299

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Russell Investments Group's DRNA Position: Q4 2021 in Review

Russell Investments Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 206,845 shares — an estimated $4.17M sold.

Russell Investments Group first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $6.67M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Russell Investments Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Russell Investments Group sold 206,845 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $4.17M.
Russell Investments Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
Russell Investments Group's Dicerna Pharmaceuticals, Inc. position peaked at $6.67M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Russell Investments Group's 13F filing for Q4 2021, filed 21 Jan 2022.